Literature DB >> 23330090

Release-activity: a long way from phenomenon to new drugs.

O I Epstein1.   

Abstract

Multiple dilutions of the original substance release its peculiar activity referred to as "release-activity". Although this activity originates from the initial substance, it does not depend on its negligible concentration in extreme dilutions. Thus, the terms "dose", "ultralow dose", and "homeopathic dose", do not correctly describe the release-active solutions, since the concept of dose implies the presence of some part of the original substance in a dilution with its intrinsic therapeutic potency. The data are reported on the molecular and cellular mechanisms of the mode of action of the release-active agents, some of which being introduced into clinical practice.

Mesh:

Substances:

Year:  2012        PMID: 23330090     DOI: 10.1007/s10517-012-1874-6

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN: 0007-4888            Impact factor:   0.804


  9 in total

1.  Release-active dilutions of diclofenac enhance anti-inflammatory effect of diclofenac in carrageenan-induced rat paw edema model.

Authors:  Sachin S Sakat; Kamaraj Mani; Yulia O Demidchenko; Evgeniy A Gorbunov; Sergey A Tarasov; Archna Mathur; Oleg I Epstein
Journal:  Inflammation       Date:  2014-02       Impact factor: 4.092

2.  Low Dose Medicine: theoretical background and scientific evidence.

Authors:  S Bernasconi
Journal:  Ital J Pediatr       Date:  2018-02-08       Impact factor: 2.638

Review 3.  Vascular cognitive impairment: pathophysiological mechanisms, insights into structural basis, and perspectives in specific treatments.

Authors:  Vladimir A Parfenov; Olga D Ostroumova; Tatiana M Ostroumova; Alexey I Kochetkov; Victoria V Fateeva; Kristina K Khacheva; Gulnara R Khakimova; Oleg I Epstein
Journal:  Neuropsychiatr Dis Treat       Date:  2019-05-21       Impact factor: 2.570

Review 4.  Therapeutic and Prophylactic Use of Oral, Low-Dose IFNs in Species of Veterinary Interest: Back to the Future.

Authors:  Sara Frazzini; Federica Riva; Massimo Amadori
Journal:  Vet Sci       Date:  2021-06-11

5.  Subetta treatment increases adiponectin secretion by mature human adipocytes in vitro.

Authors:  Jim Nicoll; Evgeniy A Gorbunov; Sergey A Tarasov; Oleg I Epstein
Journal:  Int J Endocrinol       Date:  2013-04-18       Impact factor: 3.257

6.  The novel oral drug Subetta exerts an antidiabetic effect in the diabetic Goto-Kakizaki rat: comparison with rosiglitazone.

Authors:  Danielle Bailbé; Erwann Philippe; Evgeniy Gorbunov; Sergey Tarasov; Oleg Epstein; Bernard Portha
Journal:  J Diabetes Res       Date:  2013-05-08       Impact factor: 4.011

7.  Novel approach to activity evaluation for release-active forms of anti-interferon-gamma antibodies based on enzyme-linked immunoassay.

Authors:  Elena S Gavrilova; Sergey A Bobrovnik; Gordon Sherriff; Andrey A Myslivets; Sergey A Tarasov; Oleg I Epstein
Journal:  PLoS One       Date:  2014-05-09       Impact factor: 3.240

8.  Use of Piezoelectric Immunosensors for Detection of Interferon-Gamma Interaction with Specific Antibodies in the Presence of Released-Active Forms of Antibodies to Interferon-Gamma.

Authors:  Elena Don; Olga Farafonova; Suzanna Pokhil; Darya Barykina; Marina Nikiforova; Darya Shulga; Alena Borshcheva; Sergey Tarasov; Tatyana Ermolaeva; Oleg Epstein
Journal:  Sensors (Basel)       Date:  2016-01-20       Impact factor: 3.576

9.  In vitro screening of major neurotransmitter systems possibly involved in the mechanism of action of antibodies to S100 protein in released-active form.

Authors:  Evgeniy A Gorbunov; Irina A Ertuzun; Evgeniya V Kachaeva; Sergey A Tarasov; Oleg I Epstein
Journal:  Neuropsychiatr Dis Treat       Date:  2015-11-03       Impact factor: 2.570

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.